Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
Halberd Corporation (OTC: HALB) has acquired NeuroSense AI Corp., a pioneering behavioral intelligence platform that combines multi-modal AI analysis with Claude AI technology. The platform analyzes three key behavioral data streams: vocal patterns, movement dynamics, and social interactions to revolutionize traumatic brain injury (TBI) research and clinical assessment.
The proprietary technology delivers clinical-grade insights through ultrasonic vocalization patterns, micro-movement analysis, and social dynamic monitoring. This innovative approach enables earlier detection of neurological changes and more quantifiable results for FDA approval processes. The platform targets the behavioral health market, projected to reach $240 billion by 2030, with applications across research institutions, clinical settings, pharmaceutical development, and military sectors.
Halberd Corporation (OTC: HALB) ha acquisito NeuroSense AI Corp., una piattaforma pionieristica di intelligenza comportamentale che combina analisi multi-modale di AI con la tecnologia Claude AI. La piattaforma analizza tre flussi principali di dati comportamentali: pattern vocali, dinamiche di movimento e interazioni sociali per rivoluzionare la ricerca e la valutazione clinica delle lesioni cerebrali traumatiche (TBI).
La tecnologia proprietaria offre approfondimenti di livello clinico attraverso pattern di vocalizzazione ultrasonica, analisi di micro-movimenti e monitoraggio delle dinamiche sociali. Questo approccio innovativo consente un rilevamento precoce dei cambiamenti neurologici e risultati più quantificabili per i processi di approvazione FDA. La piattaforma si rivolge al mercato della salute comportamentale, stimato in $240 miliardi entro il 2030, con applicazioni in istituzioni di ricerca, contesti clinici, sviluppo farmaceutico e settori militari.
Halberd Corporation (OTC: HALB) ha adquirido NeuroSense AI Corp., una plataforma pionera de inteligencia conductual que combina análisis de IA multimodal con la tecnología Claude AI. La plataforma analiza tres flujos clave de datos conductuales: patrones vocales, dinámica de movimiento e interacciones sociales para revolucionar la investigación y la evaluación clínica de lesiones cerebrales traumáticas (TBI).
La tecnología propietaria ofrece insights de grado clínico a través de patrones de vocalización ultrasónica, análisis de micro-movimiento y monitorización de dinámicas sociales. Este enfoque innovador permite una detección más temprana de cambios neurológicos y resultados más cuantificables para los procesos de aprobación de la FDA. La plataforma apunta al mercado de salud conductual, proyectado en $240 mil millones para 2030, con aplicaciones en instituciones de investigación, entornos clínicos, desarrollo farmacéutico y sectores militares.
Halberd Corporation (OTC: HALB)가 NeuroSense AI Corp.를 인수했습니다. 다중 모달 AI 분석과 Claude AI 기술을 결합한 선도적인 행동 지능 플랫폼으로, 플랫폼은 음성 패턴, 움직임의 역학, 사회적 상호작용의 세 가지 핵심 행동 데이터 흐름을 분석하여 뇌 외상(TBI) 연구 및 임상 평가를 혁신합니다.
독점 기술은 초음파 발성 패턴, 미세 움직임 분석, 사회적 역동성 모니터링을 통해 임상 등급의 통찰을 제공합니다. 이 혁신적 접근 방식은 신경학적 변화의 조기 탐지와 FDA 승인을 위한 더 정량화된 결과를 가능하게 합니다. 이 플랫폼은 2030년까지 $2400억으로 예상되는 행동 건강 시장을 목표로 하며, 연구 기관, 임상 환경, 제약 개발 및 군사 부문에 적용됩니다.
Halberd Corporation (OTC: HALB) a acquis NeuroSense AI Corp., une plateforme pionnière d’intelligence comportementale qui combine l’analyse IA multimodale avec la technologie Claude AI. La plateforme analyse trois flux de données comportementales clés : les motifs vocaux, la dynamique du mouvement et les interactions sociales pour révolutionner la recherche et l’évaluation clinique des lésions cérébrales traumatiques (TBI).
La technologie propriétaire délivre des insights de niveau clinique via des motifs de vocalisation ultrasonique, l’analyse de micro-mouvements et la surveillance des dynamiques sociales. Cette approche innovante permet une détection précoce des changements neurologiques et des résultats plus quantifiables pour les processus d’approbation par la FDA. La plateforme vise le marché de la santé comportementale, estimé à $240 milliards d’ici 2030, avec des applications dans des institutions de recherche, des environnements cliniques, le développement pharmaceutique et les secteurs militaires.
Halberd Corporation (OTC: HALB) hat NeuroSense AI Corp. übernommen, eine bahnbrechende Plattform für verhaltensbasierte Intelligenz, die multimodale KI-Analysen mit Claude AI-Technologie kombiniert. Die Plattform analysiert drei zentrale Verhaltensdatenschichten: Stimmmuster, Bewegungsdynamik und soziale Interaktionen, um die Forschung und klinische Bewertung von traumatischen Hirnverletzungen (TBI) zu revolutionieren.
Die proprietäre Technologie liefert klinisch hochwertige Einsichten durch Ultraschall-Vocalisationsmuster, Mikrobewegungsanalyse und Überwachung sozialer Dynamiken. Dieser innovative Ansatz ermöglicht eine frühere Erkennung neurologischer Veränderungen und besser quantifizierbare Ergebnisse für FDA-Zulassungsprozesse. Die Plattform richtet sich an den Markt für Verhaltensgesundheit, der bis 2030 auf $240 Milliarden geschätzt wird, mit Anwendungsbereichen in Forschungseinrichtungen, klinischen Einrichtungen, pharmazeutischer Entwicklung und Militärsektoren.
Halberd Corporation (OTC: HALB) استحوذت على NeuroSense AI Corp.، وهي منصة رائدة للذكاء السلوكي تجمع بين تحليل الذكاء الاصطناعي متعدد الوسائط وتقنية Claude AI. تحلل المنصة ثلاثة تدفقات بيانات سلوكية رئيسية: أنماط الصوت، ديناميكيات الحركة، والتفاعلات الاجتماعية لإحداث ثورة في أبحاث إصابات الدماغ المرتبطة بالإصابة Traumatic Brain Injury (TBI) والتقييم السريري.
التقنية المملوكة تقدم رؤى بمستوى سريري من خلال أنماط النطق بالموجات فوق صوتية، وتحليل الحركة الدقيقة، ومراقبة الديناميكيات الاجتماعية. هذه المقاربة المبتكرة تتيح الكشف المبكر عن التغيرات العصبية ونتائج أكثر قابلية للقياس لعمليات موافقات FDA. تستهدف المنصة سوق الصحة السلوكية، المتوقع أن يصل إلى $240 مليار بحلول 2030، مع تطبيقات في مؤسسات البحث، والإعدادات السريرية، وتطوير الأدوية، والقطاعات العسكرية.
Halberd Corporation (OTC: HALB) 已收购 NeuroSense AI Corp.，这是一个将多模态人工智能分析与 Claude AI 技术相结合的前沿行为智能平台。该平台分析三个关键行为数据流：声音模式、运动动态和社交互动，以革新创伤性脑损伤（TBI）研究和临床评估。
该专有技术通过超声发声模式、微动作分析和社交动态监测，提供临床级见解。这一创新方法可更早检测到神经变化，并为 FDA 审批过程提供更可量化的结果。该平台面向行为健康市场，预测到 2030 年将达到 $2400 亿，应用覆盖研究机构、临床环境、药物开发及军事领域。
- First-mover advantage in commercializing Claude AI-powered behavioral analysis
- Platform enables detection of neurological changes weeks/months before traditional methods
- Multiple data streams provide more quantifiable and evident test results
- Potential to accelerate FDA approval process through enhanced data quality
- Targeting rapidly growing behavioral health market worth $240B by 2030
- Wide application potential across research, clinical, pharmaceutical, and military sectors
- Early-stage technology requiring regulatory validation and approvals
- Implementation and integration costs with existing clinical workflows not disclosed
- Potential cybersecurity and HIPAA compliance challenges with cloud-native architecture
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications
JACKSON CENTER, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment. The proprietary platform represents the first commercial development of multi-modal behavioral signal fusion.
Breaking New Ground in AI-Powered Healthcare
NeuroSense AI will address a critical gap, starting with TBI research, where traditional observational methods often fail to capture subtle neurological changes that precede clinical manifestations. The platform's innovative approach fuses three distinct behavioral data streams – vocal patterns, movement dynamics, and social interactions – through advanced AI algorithms powered by Claude AI technology. Among each of those three data streams are multiple data points, ripe for analysis to better assess deviations from norms that may evidence, for example, toxic buildup of antigens associated with the targeted disease state or affliction.
"NeuroSense AI represents a paradigm shift in how we understand and monitor brain health," commented William Hartman, CEO of Halberd Corporation. "By combining cutting-edge sensor technology with artificial intelligence, we're providing researchers and clinicians with tools that can detect neurological changes weeks or months before traditional methods. Moreover, the degree of such deviations from the norm become more demonstrable and quantifiable. The magnitude of each such deviation, coupled with the greater number of variables/data points to test, will render test results more evident. Presumably, less testing would be required before the requisite level of proof for the FDA is achieved. This could be particularly revolutionary, considering the amount of time required to achieve the appropriate standard of proof of efficacy. We intend to implement this capability into the upcoming Phase 2 animal testing being planned at Mississippi State University."
Proprietary Technology Delivers Clinical-Grade Insights
The NeuroSense AI platform leverages proprietary algorithms to analyze and often quantify:
- Ultrasonic Vocalization Patterns: Advanced audio processing detects stress indicators, frequency variations, and temporal changes in vocal behavior particularly in animal research and testing;
- Micro-Movement Analysis: Computer vision technology tracks subtle changes in grooming, mobility, and spatial behavior patterns;
- Social Dynamic Monitoring: AI-powered assessment of interaction patterns, engagement timing, and social preference indicators.
This multi-modal approach generates comprehensive behavioral fingerprints that enable researchers to track recovery trajectories, assess treatment efficacy, and identify early warning signs of neurological decline with unprecedented accuracy. And, with the multiplicity of data points, test results become far more quantifiable and the results far more evident.
First-Mover Advantage in Billion-Dollar Market
The global behavioral health market is projected to reach
"We're not just launching a product – we're creating an entirely new category of AI-powered behavioral intelligence," said the platform's lead developer. "The combination of real-time multi-modal analysis with advanced AI interpretation has never before been achieved in a commercial platform."
Immediate Applications Across Multiple Markets
Research Institutions: Universities and research centers can leverage NeuroSense AI to accelerate TBI studies, improve data quality, and publish breakthrough research with unprecedented behavioral insights.
Clinical Applications: Hospitals and rehabilitation centers gain objective tools for tracking patient progress, optimizing treatment protocols, and providing evidence-based care recommendations. And those tools become far more potent, given the multiple data points, thus facilitating much more quantifiable results.
Pharmaceutical Development: Drug developers can utilize the platform for clinical trials, biomarker discovery, and regulatory submissions with robust behavioral endpoint data.
Government and Military: Defense applications include personnel assessment, injury evaluation, and long-term health monitoring for service members.
Technical Innovation Meets Regulatory Readiness
Halberd’s NeuroSense AI is being implemented to accord with FDA regulatory pathways in mind, featuring comprehensive documentation, validation protocols, and clinical-grade accuracy standards. The platform's cloud-native architecture will ensure scalability from single-subject studies to large multi-site clinical trials.
Key technical capabilities include:
- Real-time behavioral analysis and scoring
- Automated clinical report generation
- Longitudinal trend analysis and predictive modeling
- Integration with existing research and clinical workflows
- HIPAA-compliant data security and privacy protection
Investment in Future Innovation
The NeuroSense AI development initiative represents Halberd's strategic commitment to AI-powered healthcare innovation. The Company plans additional platform expansions including human clinical applications, consumer wellness monitoring, and advanced predictive analytics capabilities.
"This is just the beginning," emphasized Hartman. "NeuroSense AI will establish our foundation in behavioral intelligence, but we see applications extending far beyond TBI research into general brain health, aging, and cognitive wellness monitoring."
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About NeuroSense AI
NeuroSense AI Corp. is an
The platform integrates ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring through Claude AI-powered interpretation to provide unprecedented insights into brain health and recovery patterns. Initially designed for preclinical TBI research in animal models, NeuroSense AI Corp's cloud-native architecture enables scalable deployment from individual research labs to large multi-site clinical trials, with future applications extending to human clinical assessment and brain health monitoring.
The platform represents the first commercial application of AI-driven behavioral signal fusion technology, positioning Halberd Corporation and its partners at the forefront of next-generation neurological research capabilities.
About Halberd Corporation.
Halberd Corporation (OTC: HALB) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company's portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation's business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
FAQ
What is the NeuroSense AI platform acquired by Halberd Corporation (OTC: HALB)?
How does Halberd's NeuroSense AI technology work?
What is the market potential for Halberd's NeuroSense AI platform?
What are the main applications of Halberd's NeuroSense AI platform?
How will NeuroSense AI impact Halberd's clinical trials?
